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AbstrACt
Introduction Recent evidence suggests an underlying 
movement disruption may be a core component of autism 
spectrum disorder (ASD) and a new, accessible early 
biomarker. Mobile smart technologies such as iPads 
contain inertial movement and touch screen sensors 
capable of recording subsecond movement patterns 
during gameplay. A previous pilot study employed machine 
learning analysis of motor patterns recorded from children 
3–5 years old. It identified those with ASD from age-
matched and gender-matched controls with 93% accuracy, 
presenting an attractive assessment method suitable for 
use in the home, clinic or classroom.
Methods and analysis This is a phase III prospective, 
diagnostic classification study designed according 
to the Standards for Reporting Diagnostic Accuracy 
Studies guidelines. Three cohorts are investigated: 
children typically developing (TD); children with a clinical 
diagnosis of ASD and children with a diagnosis of another 
neurodevelopmental disorder (OND) that is not ASD. The 
study will be completed in Glasgow, UK and Gothenburg, 
Sweden. The recruitment target is 760 children (280 TD, 
280 ASD and 200 OND). Children play two games on 
the iPad then a third party data acquisition and analysis 
algorithm (Play.Care, Harimata) will classify the data as 
positively or negatively associated with ASD. The results 
are blind until data collection is complete, when the 
algorithm’s classification will be compared against medical 
diagnosis. Furthermore, parents of participants in the 
ASD and OND groups will complete three questionnaires: 
Strengths and Difficulties Questionnaire; Early 
Symptomatic Syndromes Eliciting Neurodevelopmental 
Clinical Examinations Questionnaire and the Adaptive 
Behavioural Assessment System-3 or Vineland Adaptive 
Behavior Scales-II. The primary outcome measure is 
sensitivity and specificity of Play.Care to differentiate ASD 
children from TD children. Secondary outcomes measures 
include the accuracy of Play.Care to differentiate ASD 
children from OND children.
Ethics and dissemination This study was approved by 
the West of Scotland Research Ethics Service Committee 3 
and the University of Strathclyde Ethics Committee. Results 
will be disseminated in peer-reviewed publications and at 
international scientific conferences. 
trial registration number NCT03438994; Pre-results.
IntroduCtIon
Autism spectrum disorder (ASD) is a child-
hood neurodevelopmental disorder with a 
prevalence estimated as high as 1 in 59 chil-
dren in the USA.1 In the UK, ca. 700 000 
individuals live with autism2 and the aggre-
gate annual cost of healthcare and support 
is £28 billion.3 Early identification and conse-
quent early therapeutic intervention may 
afford family and caregivers opportunity to 
adjust, and can trigger early healthcare inter-
vention and children’s services support. Such 
provision can produce significant, lifelong 
health and economic benefit.4–7 
Early diagnosis of children with autism 
remains complex and can be difficult to 
obtain. Diagnosis currently relies on specialist 
medical expertise with diagnostic instrumen-
tation dependent on subjectively rated scores 
during child observations, parent interviews 
and testing. These instruments are time 
strengths and limitations of this study
 ► This study tests the accuracy of a new computation-
al serious game assessment for the early identifica-
tion of autism in preschool children.
 ► It is the first phase 3 diagnostic study to evaluate 
an iPad-based serious game assessment for autism 
spectrum disorder.
 ► A  computational analysis of motor pattern vari-
ables, rather than social and emotional variables, is 
employed.
 ► Novel data collection methods exploit the 
touch screen and inertial sensors for accurate, re-
liable movement measurement of children during 
gameplay.
 ► Children with clinical diagnoses of autism are com-
pared with typically developing controls and children 
with other neurodevelopmental disorders that are 
not autism.
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consuming, clinically demanding and can be poorly vali-
dated against population controls. Medical diagnosis can 
be withheld for many years due to wait-list times or uncer-
tainty in clinical diagnostic fit, and schools and families 
can struggle not knowing whether or not a child formally 
requires additional support needs.8 9
Recent identification of motor disturbance in young 
children who develop ASD presents a new target for early 
assessment.10 11 ASD is typically considered a social and 
emotional disorder. Therefore, current diagnostic instru-
ments directly address social and emotional aspects of 
the syndrome. However, motor control underpins social 
engagement, emotional expression, linguistic and cogni-
tive development,12–17 and its precise subsecond form is 
now accessible to non-invasive, ecologically valid assess-
ment methods from the neonatal stage onward. These 
methods of motor analysis  can detect risk for neuro-
developmental disorder well before current methods 
allow,18–21 but more work is needed to better characterise 
these motor signatures. In particular, characterisation of 
an autism-specific motor signature may serve as an acces-
sible, non-invasive biomarker of the disorder for its early 
identification, but more work is needed to better define 
its specificity within the broad clinical population.22
Children with ASD exhibit a motor signature with 
a disruption in the development of purposeful move-
ment,10 evident in, for example, delays in the attainment 
of motor milestones,23 24 poor coordination,25 26 unusual 
gait patterns27–29 and difficulties in gross and fine motor 
skills.30 In a meta-analysis of all evidence, Fournier et al11 
concluded motor disruption to be a core feature of ASD. 
This motor perspective is beginning to gain significant 
clinical and research interest31 and although movement 
differences in autism have not yet entered into the diag-
nostic criteria, the Diagnostic and Statistical Manual of 
Mental Disorders (DSM–5)32 now includes ‘awkward or 
clumsy gait’ as an associated symptom. More work is now 
required to characterise how these motor differences 
manifest across the spectrum22 and to identify their aeti-
ology.33 34 Motor signs identified in autism require differ-
entiation from those that extend across the wider spectrum 
of Early Symptomatic Syndromes Eliciting Neurodevelop-
mental  Clinical Examination (ESSENCE).35
Recently, technological developments have minia-
turised inertial movement unit (IMU) sensors that 
now include triaxial accelerometers, gyroscopes and 
magnetometers, together with touch-sensitive screens 
integrated into mobile consumer smart devices such as 
phones, tablets and wearable devices such as wristbands 
and watches. These new devices provide unprecedented 
access to motor information with high levels of accuracy 
and reliability previously restricted to high-end research 
or clinical laboratories.
At the same time, an emerging field of ‘serious games’ 
has established a new paradigm for engaging children 
with autism in psychological assessment or intervention 
in fun and playful manners while retaining a ‘serious’ 
scientific agenda.36–39 Smart tablet serious games are 
an especially attractive format, because children with 
ASD do not readily share the same social intentions as the 
researcher. On the other hand, children with ASD and 
typically developing (TD) children alike typically enjoy 
screen-based games and will engage these freely of their 
own volition, presenting an attractive and ecologically 
valid paradigm for assessment.
In previous work, Anzulewicz et al18 tested a novel, 
serious smart tablet game for early identification of young 
children with autism. Two attractive educational cartoon 
games (Duckie Deck, http:// duckiedeck. com) were engi-
neered with bespoke code to collect sensor data (touch 
screen and triaxial accelerometer and gyroscope) as the 
children engaged for 5 min with each game. Machine 
learning analysis identified those children diagnosed 
with autism with 93% accuracy, proving the principle 
that smart game identification of ASD in children was a 
viable solution for assessment. Furthermore, this meth-
odology required no professional training to deploy, no 
verbal instructions were required to engage the child, 
and only limited supervision was necessary. The result of 
the assessment was purely statistical; no subjective coding 
was required. Thus, we proposed this serious game digital 
health instrument could serve as an attractive addition 
to the diagnostician’s tool box, as a paediatric public 
health screening tool, or for teachers and psychologists 
in schools.
This game is now developed into a commercial product 
called Play.Care that is entering its final stages of prepa-
ration by Harimata sp. z o.o. (https:// harimata. pl/) with 
support from a European Union Horizon 2020 Small to 
Medium Enterprise Instrument (grant No. 756079) to 
maximise its development and availability. This diagnostic 
study is a part of that grant to test with gold-standard 
methodology the classification accuracy of the serious 
game assessment, and therefore its value in educational, 
clinical and population screening contexts, or as a tool in 
clinical diagnosis.
A current best performance for a validated subcom-
ponent of the gold standard in autism diagnosis, the 
Autism Diagnostic Observation Schedule (ADOS) V.2, 
yields diagnostic performance of, at most, 91% sensi-
tivity and 71% specificity, or 82% sensitivity and 88% 
specificity when the algorithm is adjusted to increase 
specificity.40 In our previous pilot work, the Play.Care 
iPad serious game assessment demonstrated a sensi-
tivity and specificity of 83% and 85%, respectively.18 
Serious game assessment by smart device appears to be 
an attractive resource that could improve sensitivity and 
specificity ratings, while at the same time improving 
accessibility. Moreover, the device offers a pure statis-
tical computation without the disadvantages of subjec-
tively rated codes.
The aim of this study is to validate the predictive 
value of the Play.Care for ASD diagnosis by conducting 
a multisite, controlled diagnostic study. Further aims 
include assessing the ability of Play.Care to differentiate 
ASD from other childhood developmental disorders. The 
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primary outcome measures will be sensitivity and speci-
ficity of Play.Care to detect ASD in the study  population.
Limitations inherent in the earlier pilot study are 
overcome in this diagnostic trial. The pilot study was 
based on a sample of 82 children recruited from a small 
number of specialist day-care centres in Poland. Such 
limited subject recruitment is prone to selection bias and 
site-specific effects and precludes assessment of predic-
tive value in population-based settings. Furthermore, the 
pilot study employed the same dataset to train and test 
the machine learning algorithm. It did so with 10 repe-
titions of a 10-fold cross-validation procedure that is not 
prone to overfitting. Nevertheless, it only trained and 
tested patterns on that particular dataset. To alleviate 
both concerns, this study sets out to test an adaptation 
of the algorithm previously developed and published18 
on new, blinded data obtained independently of the Play.
Care software engineers and commercial concerns in 
an international, multisite diagnostic evaluation with a 
general population and clinical cohort and with phase III 
clinical study structure and size. This trial is designed to 
test the Play.Care assessment to determine its generalised, 
real-world prediction rates across the range of possible 
ASD expression, as well as against TD and other neuro-
developmental disorder (OND) variability. Should the 
sensitivity and specificity of the assessment fall within clin-
ically useful levels comparable to or exceeding current 
observer-rated tests (ADOS-2, Autism Diagnostic Inter-
view-Revised, ADI-R), we expect this instrument to be an 
attractive and useful addition to the assessment and diag-
nostic tool box, accessible to a wide range of profes-
sionals in psychiatry, paediatrics and specialist children’s 
services, and those in education. This solution is attractive 
and timely, and benefits from a surge in machine learning 
analysis of smart tech data. In our case, this is a fun, useful 
and mobile serious game for autism assessment.
MEthods And AnAlysIs
study design
This study is a phase III prospective, diagnostic classi-
fication study. The protocol follows the Standards for 
Reporting Diagnostic Accuracy Studies guidelines.41 The 
study is a multicentre, international trial based in Glasgow, 
Scotland, UK and Gothenburg, Sweden. The Glasgow 
cohort comprises a clinical sample and the Gothenburg 
cohort comprises a general population sample. The study 
has three groups of participants recruited across two sites 
(table 1): children who have received a clinical diagnosis 
of ASD; children who have received a clinical diagnosis 
of an (OND; see table 2 for inclusion/exclusion criteria); 
and children TD. The recruitment phase of the study runs 
from 1 January 2018 to 30 June 2019 with data analysis for 
Table 1 Participant numbers across groups and sites
Site ASD OND TD Total
Glasgow 100 140 180 420
Gothenburg 180 60 100 340
Total 280 200 280 760
ASD, Autism Spectrum Disorder; OND, Other neurodevelopmental 
disorder; TD, typically developing. 
Table 2 Participant inclusion and exclusion criteria
Group Inclusion criteria Exclusion criteria
All participants Aged 30 months to 5 years 11 months
Participants with a diagnosis of ASD Diagnosis of autism spectrum disorder on 
the basis of DSM-5 criteria or equivalent 
ICD-10 framework
Uncorrected sensory (visual, hearing) 
impairments
Presence of any motor impairments or 
behavioural impairment that may obstruct 
testing
Participants with a diagnosis of OND Other childhood developmental 
disorders including, but not limited to 
intellectual disability, non-verbal disability, 
communication disability, attention deficit 
hyperactivity disorder and developmental 
coordination disorder, Down’s syndrome 
and cerebral palsy.
Subclinical or secondary expressions of 
ASD
Uncorrected hearing or vision impairments
TD participants Within age range Diagnosis or suspicion of
 ► Neuropathology
 ► Psychopathology
 ► Sensory or motor disorder including mild 
tremors
ASD, Autism Spectrum Disorder; OND, Other neurodevelopmental disorder; TD, typically developing. 
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primary and secondary outcome measures concluding 
and reports submitted by 31 October 2019.
Patient and public involvement
The research questions addressed in this study were the 
result of previous dialogue between research, digital 
health, commercialisation and clinical, educational, 
and parental need. Demand for early, accessible and 
computationally accurate assessment of ASD was found 
to be growing within the context of a rise in awareness 
and incidence of diagnosed autism. Yet, wait-list times 
remained high and demand on clinician time increased. 
An accessible instrument was needed that could identify 
autism and differentiate it from ONDs—the primary and 
secondary outcome measures of this study—with ease 
and reduced expert involvement. Patient involvement 
helped inform recruitment patterns of this diagnostic 
study, particularly to fit around family care and education 
patterns, and especially the children’s daily routine. The 
latter was an important consideration for timing subject 
engagement. Educators and clinicians assisted with the 
early stages of pilot protocol development, ensuring the 
Play.Care test phase would fit alongside the normal day 
routine in the nursery, school, clinic, or in some cases, in 
the home.
Participants
A total of 760 children aged 30 months to 5 years 11 
months will be recruited. Table 1 illustrates the partic-
ipant numbers between sites and groups and table 2 
details inclusion and exclusion criteria for each group.
Group sizes were decided on by assuming Play.Care 
will achieve a moderate 85% sensitivity. In this case, a 
study with 200 children with ASD will yield a confidence 
interval  (CI) with a width of ±4.9%, that is, the final sensi-
tivity calculation will be accurate to within this range. 
The target recruitment size for this group is 280 chil-
dren to afford some reduction in sensitivity or a signifi-
cant non-completion or under-recruitment rate while 
preserving a narrow CI. The wider population recruited 
in this study in comparison to the earlier study may reduce 
sensitivity of the algorithm’s prediction, inclusion of low 
functioning children with ASD increases the likelihood of 
disengagement with or disinterest in the Play.Care assess-
ment, and the new recruitment strategies employed in 
this study may present recruitment challenges. Assuming 
a similar level of specificity, the same precision will be 
obtained with 200 TD children. Furthermore, if the sensi-
tivity (or specificity) is as high as 90%, there will be 80% 
power to show that the sensitivity (or specificity) exceeds 
83.0%, and 90% power to show it exceeds 81.9%. On the 
other hand, if the sensitivity (or specificity) is only 70%, 
there will be 91% power to show that it is below 80%. That 
is, if the Play.Care assessment is underperforming, which 
is the major concern of healthcare services, this study has 
a high probability of detecting it.
For the Glasgow cohort, recruitment of children with 
ASD or OND will be facilitated through the National 
Health Service (NHS) Greater Glasgow and Clyde 
Specialist Children’s Services, other specialist children’s 
centres, nurseries and schools. ASD and OND recruit-
ment will occur via two streams. The first will recruit 
children who receive a positive diagnosis of ASD or OND 
following an assessment at an NHS clinic. The second 
will recruit children already diagnosed with ASD or OND 
from specialist nurseries, preschools and development 
centres. TD children will be recruited from local private 
nurseries in the Greater Glasgow area.
The Gothenburg cohort is a general population sample 
as all children are screened for ASD within the Gothen-
burg area at 30 months. Families of children screened 
positively for ASD are referred to the Gillberg Neuro-
psychiatry Centre (GNC) in Gothenburg for neuropsy-
chiatric assessment and it is at this stage that families 
will be made aware of the study and asked if they would 
like to participate. OND children in Gothenburg will 
be recruited through speech and language therapists in 
collaboration with the GNC.
diagnostic device
The diagnostic tool under assessment in this study is the 
Play.Care iPad mini application, developed by Harimata 
sp. z o.o., Kraków, Poland. The assessment consists of 
two serious games played on the iPad. The first is called 
‘sharing’ and requires the child to tap a piece of food 
to split it into four pieces, available for sharing with four 
cartoon game characters waiting patiently (figure 1A). 
The second game is called ‘creativity’ and requires the 
child to trace the outline of a drawing and then colour it 
in (figure 1B). Each gameplay session consists of a 2 min 
training phase where the researcher and/or parent can 
assist the child, and a 5 min assessment phase where the 
child must play unassisted. Data are collected for anal-
ysis only from the 5 min assessment phase. Following 
completion of the assessment, no further participation is 
required.
Figure 1 Play.Care assessment serious games. (A) 
‘Sharing’. The child taps the fruit to divide it into four pieces 
for sharing among the game characters. When all four 
characters have a slice of fruit, they express happiness 
for three seconds before the fruit is replaced with another 
food and the characters return to their original positions. (B) 
‘Creativity’. The child is free to choose an object or animal 
they wish to trace and then colour in freely by choosing a 
colour form the colour wheel. If the child is satisfied with their 
colouring, a new shape can be chosen by selecting the green 
button at the top of the screen, and the process repeats. 
Reproduced from Anzulewicz et al. (2016).
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Anzulewicz et al18 details the data analytics employed, 
including identification of movement patterns by calcu-
lation of more than 200 ‘features’ that are assessed by 
an algorithm developed by machine learning. This algo-
rithm statistically determines whether or not a particular 
child’s gameplay fits a diagnostic classification. It delivers 
a statistical prediction.
The gameplay data are collected by two sets of sensors 
within the iPad (figure 2): (1) the touch screen sensor 
records the Cartesian coordinate of the touch and its 
displacement as a gesture travels across the screen with a 
sampling rate of ca. 60 times per second; and (2) a triaxial 
accelerometer and gyroscope IMU sensor that detects the 
small accelerations and rotations of the iPad device with 
a sampling rate of ca. 100 times per second as the child’s 
fingers impact on the screen and push into it giving 
subtle, but significant displacive forces during a gesture. 
More than 200 movement ‘features’ are calculated from 
the raw sensor signals to characterise the child’s gameplay. 
These include, for example, for the touch screen sensors, 
the duration of a gesture, its maximum velocity, devi-
ation from a straight line, its peak acceleration and the 
variance of these parameters across a gameplay session. 
Features from the raw IMU sensors are similarly extracted 
by calculating, for example, peak acceleration and rota-
tion for each axis, their means and SDs. These features 
are described in full in Anzulewicz et al.18 Altogether, 10 
repetitions of a 10-fold cross-validation procedure were 
carried out with Regularized Greedy Forest42 machine 
learning enhanced with additional data collected by Hari-
mata in collaboration with the University of Strathclyde 
prior to this study to produce the algorithm employed in 
this study. The algorithm is fixed for the duration of the 
study.
The iPads used in this study are commercially available 
Apple products currently widely used for leisure, business 
and research. The iPad specifications employed here are 
as follows: white or black bevel, silver back iPad mini 4, 
128 GB. The iOS version will be the latest version avail-
able on purchase of the iPads. These specifications will 
remain fixed for the duration of the study. Furthermore, 
software updates will be switched off to prevent automatic 
updates of iOS which may alter the sampling rate of the 
internal gyroscope and accelerometers.
Procedure
Potential participants in the ASD and OND assessment 
stream will first be approached by the clinician under-
taking the assessment. The family will be presented with 
the patient information sheet (PIS) following a positive 
diagnosis and if the clinician judges them to be suitable 
participants. The family will complete an interest slip 
indicating that they are willing to be further contacted 
by the research team regarding the study. This method 
was adopted to allow participation to be strictly ‘opt-in’ 
and to prevent the research team contacting families 
who had not expressed an interest in participating. After 
a minimum period of 24 hours, the research team will 
contact interested families to ask if they would like to 
participate and to arrange a data collection appointment.
Potential participants in the ASD and OND already 
diagnosed stream will be first approached at their child’s 
preschool where the research team will introduce the 
study during a parent’s evening or similar event. At this 
point, the PIS will be made available and families who 
are interested will complete an interest slip, as above, 
and after a minimum of 24 hours the research team will 
contact them.
Potential participants who are TD will be recruited 
through local private nurseries. Nursery staff will circu-
late the PIS among parents and those who wish their 
child to participate will return a completed consent 
form to the nursery. Prior to completing the Play.Care 
assessment, informed consent will be given by the child’s 
parents or caregivers. The researcher will then complete 
a paper-based case report form (CRF) for participants 
in the ASD and OND groups which details study ID, 
Scottish Community Health Index (‘CHI’) number, 
name, address, postal code, phone number and general 
practitioner details. Participants’ CHI numbers will be 
recorded to allow follow-up for up to 10 years following 
participation. This will provide potential future insight 
into whether diagnoses remain consistent into adoles-
cence and whether any other diagnoses are received. Any 
further diagnoses can then be compared with the iPad 
data to determine any correlations between new diag-
noses and movement characteristics in childhood.
An additional electronic CRF (eCRF) will be completed 
detailing the child’s state of arousal and interest on 
the day of data collection, and for the ASD and OND 
groups, data from a number of additional psychometric 
instruments including the Strengths and Difficulties 
Questionnaire (SDQ), the ESSENCE Questionnaire 
(ESSENCE-Q) and the Adaptive Behaviour Assessment 
System (ABAS) at Glasgow and the Vineland Adaptive 
Behavior Scale in Gothenburg will be recorded. In some 
cases, additional data will be recorded from instruments 
employed as part of the child’s neuropsychiatric assess-
ment: Wechsler Preschool and Primary Scale of Intelli-
gence ; ADI-R; and ADOS-2. The diagnostic criteria that 
determine a child’s diagnosis (International Statistical 
Classification of Diseases and Related Health Problems 
10th Revision (ICD-10) or DSM 5) will be recorded. 
Figure 2 Movement data acquisition. (A) A child engages 
freely with the serious game. The tablet is protected by 
a bumper and placed firmly on a table. Movement data 
are acquired from (B) the touch screen and (C) the inertial 
movement unit sensor that detect the kinematics and 
contact forces of a gesture, respectively. Adapted from 
Anzulewicz et al. (2016).
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These psychometric instruments will be completed at an 
appropriate time during or following the data collection 
appointment. Additionally, the Glasgow TD group will 
also carry out the ESSENCE-Q, SDQ and ABAS where 
possible.
Following completion of the CRF and eCRF, the child 
will complete the Play.Care assessment. During the 
assessment, the iPad will be protected within a spongy 
back cover and bumper (iPad Mini2 Air Protect, Belkin, 
USA) and will be placed flat on the table top, where it will 
remain for the duration of the assessment. Parents/care-
givers will have the option to consent to their child being 
videotaped during the assessment. If consent is given, a 
video camera will be setup and recording will begin prior 
to the child starting the assessment.
If a participant is unable to complete the assessment 
(eg, they become distracted or distressed), eCRF and 
CRF data will still be recorded and the participant will 
remain a subject in the study. This group will be classified 
as ‘Play.Care incompletes’ and will provide insight into 
the clinical applicability of the assessment. This group 
will be monitored at monthly intervals. If the rate of Play.
Care incompletes reaches a level where it will impact the 
statistical power of the study, administration protocols will 
be reviewed and adjusted to ensure best possible compli-
ance. This criterion will apply to the Glasgow cohort of 
participants only. The Gothenburg cohort is a general 
population sample and therefore participation cannot 
be controlled dependent on failure rates. If a participant 
does not have a confirmed clinical diagnosis by the end of 
the study, they will fall into the category of ‘diagnosis fail-
ures’. The acceptable level of diagnosis failures is 7.5%, 
or, up to 21 subjects in the ASD group and 15 in the OND 
group.
Throughout the data collection phase, all members of 
the research team, the trial consortium and Harimata 
will be blinded to the Play.Care diagnostic prediction 
until all data have been collected. Following data collec-
tion, clinical diagnoses will be compared with Play.Care 
diagnostic predictions. The primary outcome measure is 
the ability of Play.Care to identify ASD cases within the 
general population (Gothenburg) and clinical popula-
tion (Glasgow) by assessing classification efficacy against 
TD children. The secondary outcome measures are the 
ability of Play.Care to differentiate these ASD children 
from OND children.
ConClusIons
This is the first phase 3 equivalent diagnostic study to test 
the predictive diagnostic accuracy of a smart tablet serious 
game for the early detection of autism in preschool chil-
dren. The system is based on computational analysis 
of motor patterns inherent in the smart tablet sensor 
gameplay data, with pilot data suggesting sensitivity 
and specificity comparable or exceeding the current 
gold standard. This new system offers the benefit of rapid 
computational analysis with no lengthy subjectively rated 
clinician-led elements to it, rather the system engages the 
child’s interest in an attractive tablet-based serious game 
with raw sensor data analysed by classification algorithm. 
The instrument’s computational accuracy is tested in this 
multisite diagnostic study of 760 children.
dIssEMInAtIon
Following completion of data collection, results will be 
disseminated in the peer-reviewed scientific literature, at 
national and international scientific conferences,  on  the 
Laboratory for Innovation in Autism website (https://
www. strath. ac. uk/ research/ innovationinautism/) and 
by final report to Harimata sp. z o.o. and the European 
Commission.  A lay summary of the study results will be 
available for participating families.
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